A physiologically based pharmacokinetic model for V937 oncolytic virus in mice DOI Creative Commons
Sara Peribañez-Dominguez, Zinnia P. Parra‐Guillén,

Tomoko Freshwater

и другие.

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Сен. 13, 2023

Introduction: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability selectively infect and replicate cancer cells, triggering direct and/or immune-induced tumor lysis. However, the mechanisms governing OV pharmacokinetics are still poorly understood. This work aims develop physiologically based pharmacokinetic model of OV, V937, non-tumor-bearing mice get quantitative understanding its elimination tissue uptake processes. Materials methods: Model development was performed using data obtained from 60 mice. Viral levels were quantified eight tissues after single intravenous V937 dose. An external dataset used for validation. test set included multiple-dose experiments with different routes administration. distribution each organ described physiological structure on mouse-specific blood flows volumes. Analyses non-linear mixed-effects approach NONMEM 7.4. Results: showed drop 10 8 5 copies/µg RNA at day 1 blood, reflected high estimate total clearance (18.2 mL/h). A well-stirred provided an adequate description all organs except muscle heart, where saturable process improved description. The highest numbers viral copies observed brain, lymph node, kidney, liver, lung, spleen first injection. On other hand, maximum amount muscle, pancreas occurred 3 days Conclusion: To best our knowledge, this is developed characterize biodistribution, representing relevant source knowledge regarding vivo behavior OVs. can be further expanded by adding compartment, OVs could replicate.

Язык: Английский

Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway DOI Creative Commons
Jingyi Tan, Jiayu Zhang, Cheng Hu

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2024, Номер 14(6), С. 2554 - 2566

Опубликована: Март 11, 2024

Oncolytic viruses (OVs), a group of replication-competent that can selectively infect and kill cancer cells while leaving healthy intact, are emerging as promising living anticancer agents. Unlike traditional drugs composed non-replicating compounds or biomolecules, the replicative nature confer unique pharmacokinetic properties require further studies. Despite some pharmacokinetics studies OVs, mechanistic insights into connection between OV antitumor efficacy remain vague. Here, we characterized profile oncolytic virus M1 (OVM) in immunocompetent mouse tumor models identified JAK‒STAT pathway key modulator OVM pharmacokinetics. By suppressing pathway, early ameliorated, leading to enhanced tumor-specific viral accumulation, increased AUC Cmax, improved efficacy. Rather than compromising immunity after inhibition, promotes T cell recruitment activation microenvironment, providing an optimal opportunity for therapeutic outcome immune checkpoint blockade, such anti-PD-L1. Taken together, this study advances our understanding pharmacokinetic-pharmacodynamic relationship therapy.

Язык: Английский

Процитировано

3

Threshold dynamics of a stochastic tumor-immune model combined oncolytic virus and chimeric antigen receptor T cell therapies DOI
Tong Zhou, Jin Yang, Yuanshun Tan

и другие.

Chaos Solitons & Fractals, Год журнала: 2025, Номер 197, С. 116418 - 116418

Опубликована: Апрель 25, 2025

Язык: Английский

Процитировано

0

A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept DOI Creative Commons
Khaphetsi Joseph Mahasa, Rachid Ouifki, Amina Eladdadi

и другие.

Mathematical Biosciences & Engineering, Год журнала: 2022, Номер 19(5), С. 4429 - 4457

Опубликована: Янв. 1, 2022

Combining chimeric antigen receptor T (CAR-T) cells with oncolytic viruses (OVs) has recently emerged as a promising treatment approach in preclinical studies that aim to alleviate some of the barriers faced by CAR-T cell therapy. In this study, we address means mathematical modeling main question whether single dose or multiple sequential doses during OVs therapy can have synergetic effect on tumor reduction. To end, propose an ordinary differential equations-based model virus-induced synergism investigate potential effects different regimes could result efficacious combination against populations. Model simulations show that, while is inadequate eliminate all cells, combining same successfully absence synergism. However, presence synergism, fails tumor. Furthermore, it shown if intensity synergy and/or virus potency high, then induced response inhibit oncolysis. Additionally, more robust synergistic reduction when and are administered simultaneously compared where first after OV injection. Our findings suggest seems unlikely be effective included genetically engineering viral vectors.

Язык: Английский

Процитировано

13

Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically‐Based Modeling DOI Open Access
Zinnia P. Parra‐Guillén, Aymara Sancho‐Araiz,

Kapil Mayawala

и другие.

Clinical Pharmacology & Therapeutics, Год журнала: 2023, Номер 114(3), С. 623 - 632

Опубликована: Май 12, 2023

Oncolytic viruses (OVs) represent a potential therapeutic strategy in cancer treatment. However, there is currently lack of comprehensive quantitative models characterizing clinical OV kinetics and distribution to the tumor. In this work, we present mechanistic modeling framework for V937 OV, after intratumoral (i.t.) or intravascular (i.v.) administration patients with cancer. A minimal physiologically-based pharmacokinetic model was built characterize biodistribution OVs humans. Viral dynamics incorporated at i.t. cellular level linked tumor response, enabling characterization direct killing triggered by death infected cells an indirect induced immune response. The provided adequate description changes mRNA levels size obtained from phase I/II trials administration. showed prominent role viral clearance systemic circulation infectivity addition known aggressiveness on After i.v. administration, exposure predicted be several orders magnitude lower compared These differences could overcome if high virus and/or replication. Unfortunately, latter process not identified current setting. This work provides insights selecting optimal considering replication rate infectivity.

Язык: Английский

Процитировано

8

Optimal strategies of oncolytic virus-bortezomib therapy via the apoptotic, necroptotic, and oncolysis signaling network DOI Creative Commons
Donggu Lee, Aurelio A. de los Reyes V, Yangjin Kim

и другие.

Mathematical Biosciences & Engineering, Год журнала: 2024, Номер 21(3), С. 3876 - 3909

Опубликована: Янв. 1, 2024

<abstract><p>Bortezomib and oncolytic virotherapy are two emerging targeted cancer therapies. Bortezomib, a proteasome inhibitor, disrupts protein degradation in cells, leading to the accumulation of unfolded proteins that induce apoptosis. On other hand, uses genetically modified viruses (OVs) infect trigger cell lysis, activate anti-tumor response. Despite progress treatment, identifying administration protocols for therapeutic agents remains significant concern, aiming strike balance between efficacy, minimizing toxicity, administrative costs. In this work, optimal control theory was employed design cost-effective efficient co-administration bortezomib OVs could significantly diminish population cells via death program with NF$ \kappa $B-BAX-RIP1 signaling network. Both linear quadratic strategies were explored obtain practical treatment approaches by adapting necroptosis programs. Our findings demonstrated combination therapy commencing followed infusions yields an effective tumor-killing outcome. These results provide valuable guidance development clinical treatment.</p></abstract>

Язык: Английский

Процитировано

2

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication DOI Creative Commons
Richard Dambra, Andrea Matter,

Kaitlynn Graca

и другие.

Molecular Therapy — Methods & Clinical Development, Год журнала: 2022, Номер 28, С. 190 - 207

Опубликована: Дек. 28, 2022

Viral replication places oncolytic viruses (OVs) in a unique niche the field of drug pharmacokinetics (PK) as their self-amplification obscures exposure-response relationships. Moreover, standard bioanalytical techniques are unable to distinguish input from replicated products. Here, we combine two novel approaches characterize PK and biodistribution (BD) after systemic administration vesicular stomatitis virus pseudotyped with lymphocytic choriomeningitis glycoprotein (VSV-GP) healthy mice. First: decouple PK/BD versus PK/BD, developed fully characterized replication-incompetent tool that retained all other critical attributes drug. We used this approach quantify blood tissues determine its impact on BD. Second: discriminate genomic antigenomic viral RNA strands contributing dynamics tissues, an situ hybridization method using strand-specific probes assessed spatiotemporal distribution tissues. This latter demonstrated distribution, transcription, localized tissue-resident macrophages, indicating role Ultimately, our study results refined profile for replicating OV, new proposed parameters, deeper understanding OV could be applied vectors.

Язык: Английский

Процитировано

7

Mathematical Modeling of Oncolytic Virus Therapy Reveals Role of the Immune Response DOI Creative Commons

Ela Guo,

Hana M. Dobrovolny

Viruses, Год журнала: 2023, Номер 15(9), С. 1812 - 1812

Опубликована: Авг. 25, 2023

Oncolytic adenoviruses (OAds) present a promising path for cancer treatment due to their selectivity in infecting and lysing tumor cells ability stimulate the immune response. In this study, we use an ordinary differential equation (ODE) model of growth inhibited by oncolytic virus activity parameterize previous research on effect genetically re-engineered OAds A549 lung tumors murine models. We find that data are best fit accounts response, response provides mechanism elimination tumor. also parameter estimates most effective share characteristics, notably high infection rate low viral clearance rate, might be potential reasons these viruses’ efficacy delaying growth. Further studies observing E1A P19 recombined viruses different environments may further illuminate extent effects genetic modifications.

Язык: Английский

Процитировано

4

Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy DOI Creative Commons
Mary Choules, Peter L. Bonate,

Nakyo Heo

и другие.

Journal of Pharmacokinetics and Pharmacodynamics, Год журнала: 2023, Номер 51(5), С. 399 - 416

Опубликована: Окт. 17, 2023

Abstract Clinical studies have found there still exists a lack of gene therapy dose-toxicity and dose-efficacy data that causes dose selection to remain elusive. Model informed drug development (MIDD) has become standard tool implemented throughout the discovery, development, approval pharmaceutical therapies, potential inform relationships support selection. Despite this potential, MIDD approaches for immature require standardization be useful clinical programs. With goal advance therapy, in review we first provide an overview types how they differ from bioanalytical, formulation, route administration, regulatory standpoint. biological background, propose can advanced AAV-based therapies by utilizing physiological based pharmacokinetic modeling quantitative systems pharmacology holistically AAV target protein dynamics following dosing. We discuss proposed model, allowing in-depth exploration pharmacology, could key field needs treat these unmet disease populations.

Язык: Английский

Процитировано

3

A Light sheet fluorescence microscopy and machine learning-based approach to investigate drug and biomarker distribution in whole organs and tumors DOI Creative Commons
Niyanta N. Kumar,

Petr Hrobař,

Martin Vagenknecht

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Сен. 17, 2023

Abstract Tissue clearing and Light sheet fluorescence microscopy (LSFM) provide spatial information at a subcellular resolution in intact organs tumors which is significant advance over tools that limit imaging to few representative tissue sections. The distribution of drugs, targets, biomarkers can help inform relationships between exposure the site action, efficacy, safety during drug discovery. We demonstrate use LSFM investigate an oncolytic virus (OV) vasculature xenograft tumors, as well brain Aβ pathology Alzheimer’s disease (AD) mouse model. Machine learning-based image analysis developed segment showed random forest deep learning methods provided superior segmentation accuracy vs intensity-based thresholding. Sub-cellular enabled detection punctate diffuse intracellular OV profiles. investigation TgCRND8 AD model 6.5 months age evaluation plaque density different regions. utility data support quantitative systems pharmacology (QSP) physiology-based pharmacokinetics (PBPK) modeling development are also discussed. In summary, we showcase how expand our understanding macromolecular biomarker discovery development.

Язык: Английский

Процитировано

1

Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status DOI Creative Commons

Yunmeng Wang,

Ping Cheng

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2023, Номер 1870(2), С. 166962 - 166962

Опубликована: Ноя. 19, 2023

Язык: Английский

Процитировано

1